Literature DB >> 35458583

A Comprehensive Overview of the Developments of Cdc25 Phosphatase Inhibitors.

Ahmed Bakr Abdelwahab1, Eslam Reda El-Sawy2, Atef G Hanna2, Denyse Bagrel3, Gilbert Kirsch4.   

Abstract

Cdc25 phosphatases have been considered promising targets for anticancer development due to the correlation of their overexpression with a wide variety of cancers. In the last two decades, the interest in this subject has considerably increased and many publications have been launched concerning this issue. An overview is constructed based on data analysis of the results of the previous publications covering the years from 1992 to 2021. Thus, the main objective of the current review is to report the chemical structures of Cdc25s inhibitors and answer the question, how to design an inhibitor with better efficacy and lower toxicity?

Entities:  

Keywords:  Cdc25 phosphatases; computational technique; glycoside; inhibitor; quinoid; steroid

Mesh:

Substances:

Year:  2022        PMID: 35458583      PMCID: PMC9031484          DOI: 10.3390/molecules27082389

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.927


  103 in total

1.  Redox regulation of Cdc25B by cell-active quinolinediones.

Authors:  Marni Brisson; Theresa Nguyen; Peter Wipf; Beomjun Joo; Billy W Day; John S Skoko; Emanuel M Schreiber; Caleb Foster; Pallavi Bansal; John S Lazo
Journal:  Mol Pharmacol       Date:  2005-09-09       Impact factor: 4.436

2.  Structure-based de novo design and biochemical evaluation of novel Cdc25 phosphatase inhibitors.

Authors:  Hwangseo Park; Young Jae Bahn; Seong Eon Ryu
Journal:  Bioorg Med Chem Lett       Date:  2009-05-27       Impact factor: 2.823

3.  Computational design, synthesis and biological evaluation of para-quinone-based inhibitors for redox regulation of the dual-specificity phosphatase Cdc25B.

Authors:  Shahar Keinan; William D Paquette; John J Skoko; David N Beratan; Weitao Yang; Sunita Shinde; Paul A Johnston; John S Lazo; Peter Wipf
Journal:  Org Biomol Chem       Date:  2008-07-15       Impact factor: 3.876

4.  Development of a matrix-assisted laser desorption/ionization-mass spectrometry screening test to evidence reversible and irreversible inhibitors of CDC25 phosphatases.

Authors:  E Sibille; E Bana; W Chaouni; M Diederich; D Bagrel; P Chaimbault
Journal:  Anal Biochem       Date:  2012-08-16       Impact factor: 3.365

Review 5.  The role of cdc25 in checkpoints and feedback controls in the eukaryotic cell cycle.

Authors:  I Hoffmann; E Karsenti
Journal:  J Cell Sci Suppl       Date:  1994

6.  Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp.

Authors:  Shugeng Cao; Caleb Foster; Marni Brisson; John S Lazo; David G I Kingston
Journal:  Bioorg Med Chem       Date:  2005-02-15       Impact factor: 3.641

7.  Polyprenyl-hydroquinones and -furans from three marine sponges inhibit the cell cycle regulating phosphatase CDC25A.

Authors:  Ilkay Erdogan-Orhan; Bilge Sener; Salvatore de Rosa; Julia Perez-Baz; Olivier Lozach; Maryse Leost; Sergei Rakhilin; Laurent Meijer
Journal:  Nat Prod Res       Date:  2004-02       Impact factor: 2.861

8.  Cdc25B dual-specificity phosphatase inhibitors identified in a high-throughput screen of the NIH compound library.

Authors:  Paul A Johnston; Caleb A Foster; Marni Brisson Tierno; Tong Ying Shun; Sunita N Shinde; William D Paquette; Kay M Brummond; Peter Wipf; John S Lazo
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

9.  Naphthoquinone analogs as inactivators of cdc25 phosphatase.

Authors:  S W Ham; J Park; S J Lee; W Kim; K Kang; K H Choi
Journal:  Bioorg Med Chem Lett       Date:  1998-09-22       Impact factor: 2.823

10.  IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells.

Authors:  Marie-Christine Brezak; Annie Valette; Muriel Quaranta; Marie-Odile Contour-Galcera; Denis Jullien; Olivier Lavergne; Céline Frongia; Dennis Bigg; Philip G Kasprzyk; Grégoire Pierre Prevost; Bernard Ducommun
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.